Navigation Links
Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration

CEO of Dow AgroSciences Announces Milestone in Wall Street Presentation

INDIANAPOLIS, and RICHMOND, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the successful completion of a key research milestone as part of their joint Research and Commercial License Agreement. This milestone represents the successful application of Sangamo's zinc finger DNA-binding protein nuclease (ZFN(TM)) technology in precision genome editing of a native plant gene with the aim of improving a valuable trait in canola, a crop central to Dow AgroSciences' business.

"It is my pleasure to announce we have achieved another significant milestone in the validation of zinc finger protein capabilities in plants," stated Jerome Peribere, the president and CEO of Dow AgroSciences, during his presentation at the Goldman Sachs Twelfth Annual Agricultural Biotech Forum. "We have demonstrated the robust utility and flexibility of the Sangamo technology in precision editing of a native plant gene, confirming the power of zinc finger proteins to accomplish specific and targeted modifications of the plant's own genetic sequence. The technology shows potential to enable the delivery of 'designer' crops into new and existing markets."

The milestone is the first demonstration of the precise modification of the DNA sequence of an existing gene in canola designed to generate an improved trait. This further demonstrates the ability of ZFNs to act at their intended target in crops of commercial importance.

"Sangamo's technology is revolutionizing scientists' ability to modify genes in cells. The power of the ZFP platform is being harnessed by Sangamo in therapeutics, our partner Sigma-Aldrich in research reagents, and, as we heard today, by Dow AgroSciences in plant agriculture to positively effect changes in plant genomes at a speed, efficiency, and specificity which heretofore was only considered a dream," said Edward Lanphier, Sangamo's president and CEO. "Dow AgroSciences has the expertise to implement our technology successfully into its precision trait development program."

The three-year agreement initiated October 2005 provides Dow AgroSciences with access to Sangamo's proprietary ZFP technology for the development of products in plants and plant cell cultures. During the initial three-year research term, Dow AgroSciences has the option to obtain a commercial license to sell products incorporating or derived from plant cells generated using Sangamo's ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals.

Sangamo has also developed sequence-specific ZFNs for precision gene modification and targeted gene insertion. These technologies have the potential to play a major role in bringing new discoveries in genomics forward to the marketplace. The use of Sangamo's ZFP technology to enable the efficient and reproducible generation of combinations or stacks of multiple traits and the insertion of new traits could address increasing demand.

About Dow AgroSciences LLC

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top-tier agricultural company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. Dow AgroSciences provides innovative technologies for crop protection, pest and vegetation management, seeds, traits, and agricultural biotechnology to serve the world's growing population. Global sales for Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, are $3.8 billion. Learn more at

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at

This press release may contain forward-looking statements based on Dow AgroSciences LLC and Sangamo BioScience, Inc.'s current expectations. These forward-looking statements include, without limitation, references to the achievement of additional milestones under the Research and Commercial License Agreement, the anticipated execution of commercial and collaborative agreement with Dow AgroSciences, the application of Sangamo's ZFP TFs and ZFNs in plant agriculture, and the impact of milestone achievements on regulatory process and commercialization of new crop products. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Dow AgroSciences ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly report on Form 10-Q. Dow AgroSciences and Sangamo BioSciences, Inc. assume no obligation to update the forward-looking information contained in this press release.

(TM)Trademark of Sangamo Biosciences, Inc.

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
2. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
3. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
4. Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference
5. Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
6. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
7. Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast
8. Sangamo BioSciences to Present at the 2007 BIO InvestorForum
9. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
10. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
11. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015  Sorrento Therapeutics, Inc. (NASDAQ: ... treatments for cancer and associated pain, announced today that ... be presenting at the Aegis Capital Corporation 2015 ... :Event:Aegis Capital Corporation 2015 Growth ConferenceDate:Friday, October 9, ... Encore @ The Wynn in Las Vegas, NV ...
(Date:10/8/2015)... 2015 Celemics, a global pioneer of personalized ... American market with the establishment of Celemics America, Inc. ... Europe , has secured itself in the ... and sample preparation for DNA sequencing and genetic testing.  ... somatic genetic testing more accurately, quickly, and cost effectively ...
(Date:10/8/2015)... Oct. 8, 2015  Today, DuPont and Caribou ... genome editing, jointly announced a strategic alliance. As ... their respective patent portfolios, with DuPont receiving exclusive ... major row crops, and non-exclusive rights in other ... --> --> In addition, ...
(Date:10/8/2015)... Oct. 8, 2015  Sigma-Aldrich Corporation (NASDAQ: ... brand within its Applied Diagnostics and Testing ... reference standards product line with ten certified Snap-N-Spike ... bile acids and their stable-labeled internal standards. These ... lithocholic acid, taurocholic acid and native and deuterium-labeled ...
Breaking Biology Technology:
... of Wisconsin - Madison spinout company that utilizes ... investors in Madison and throughout the state of Wisconsin. ... and controllers for nanoscale research and manufacturing. , ,nPoint ... image, measure, and move objects at the sub-molecular level. ...
... Washington, DC, think tank slammed Wisconsins efforts at implementing ... could raise that score, according to the states CIO, ... Department of Administration (DOA) after the Department of ... the Center for Economic Development (CFED) missed ...
... partners feel good about doing business and working together ... of Inacom Information Systems , a Madison-based Information ... Inacom were recently recognized and awarded the Presidents Award ... in a row. According to Ingram Micro, the recipient ...
Cached Biology Technology:
(Date:9/26/2015)... 2015  Results of a TactioRPM pilot project ... at the Stanford Medicine X Conference. In a ... Connected Health Devices and Pharmacogenomics", Roger Simard ... explain how senior patients equipped with connected health ... via the TactioRPM remote patient monitoring platform were ...
(Date:9/24/2015)... September 24, 2015 ... 2015 Kerv ( ... lanserar idag världens första kontaktlösa betalningsring på ... 77 000 GBP för massproduktion via crowdfunding.  ... ) , Kerv-bärare kan göra ...
(Date:9/10/2015)... , Sept. 10, 2015 Report ... New Study Reveals Selling Opportunities and Revenue Prospects ... the future of biologics, especially new drug classes? ... will stay ahead with exclusive market data and ... explore trends, developments, results, opportunities and sales predictions. ...
Breaking Biology News(10 mins):
... Dr. Herman Scholthof, professor of plant pathology and microbiology at ... Society Fellow. , Scholthof, who also ... honor during the society,s annual meeting Aug. 4 in Portland, ... "distinguised contributions to plant pathology" or to the society. ...
... Dr. Brian Shaw, Texas A&M University assistant professor of plant ... honor based on quality, originality and quantity of published ... Award of the Mycological Society of America. Shaw has ... years. Both the National Science Foundation and the U.S. Department ...
... restoration of a 2,000-year-old bronze sculpture of the famed ... how to prevent metal corrosion, discover the safest ways ... problems. That,s the conclusion of a new study on ... issue of ACS, Crystal Growth & Design , ...
Cached Biology News:
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... imported for data analysis , Automatic grid, subgrid ... template assignment , ... Extensive background and signal options to optimize, ... results , ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
... stocks contained in standard 96-well microtiter plates. ... approximately 5,000 clones per plate. After positive ... the corresponding subplate is screened with a ... well(s). Cells from a positive well are ...
Biology Products: